D-Plus Hemolytic Uremic Syndrome
Symptoms, Doctors, Treatments, Advances & More

D-Plus Hemolytic Uremic Syndrome Overview

Save information for later
Sign Up

Learn About D-Plus Hemolytic Uremic Syndrome

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top D-Plus Hemolytic Uremic Syndrome Local Doctors?
Elite in D-Plus Hemolytic Uremic Syndrome
Pathology | Hematology | Oncology
Elite in D-Plus Hemolytic Uremic Syndrome
Pathology | Hematology | Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
Languages Spoken:
English

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine.

Elite in D-Plus Hemolytic Uremic Syndrome
Elite in D-Plus Hemolytic Uremic Syndrome
Milan, IT 

Gianluigi Ardissino practices practicing medicine in Milan, Italy. Mr. Ardissino is rated as an Elite expert by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in D-Plus Hemolytic Uremic Syndrome
Elite in D-Plus Hemolytic Uremic Syndrome

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
Languages Spoken:
English
Offers Telehealth

Spero Cataland is a Hematologist practicing medicine in Columbus, Ohio. Dr. Cataland is rated as an Elite provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy.

What are the latest D-Plus Hemolytic Uremic Syndrome Clinical Trials?
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

Summary: Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year. aHUS is a thrombotic microangiopathy (TMA) commonly caused by dysregulation of the complement system, affecting several organs, especially the kidneys. aHUS can be familial or sporadic, and approximately 50%...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Summary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.